A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection

Trial Profile

A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs PRO 140 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 20 Apr 2018 Results of long-term safety and efficacy data from two phase IIb studies published in the HIV Clinical Trials.
    • 10 Jun 2017 Biomarkers information updated
    • 14 Dec 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top